Fred Hutch, Seattle Cancer Care Alliance, and UW Medicine Complete Restructure of Partnership

Learn More

Multiple Myeloma

Multiple myeloma is a cancer that strikes plasma cells, a type of white blood cell that lives inside bone marrow. When people have this disease, their body produces too many abnormal plasma cells.

Fred Hutch is at the forefront of developing treatments for multiple myeloma. Our researchers pioneered bone marrow transplantation, one of the most significant advances in treating myeloma, lymphoma and other blood cancers. Fred Hutch investigators continue to improve bone marrow and blood stem cell transplantation for myeloma, making these therapies safer and more effective. We also pioneered the mini-transplant, a gentler version of transplantation that reduces a patient’s radiation exposure to a minimal dose, and we are bringing cutting-edge immunotherapy treatments to myeloma patients. 

A multiple myeloma blood scan.
A multiple myeloma blood scan. Fred Hutch

Multiple Myeloma Research

Our multiple myeloma research begins in the laboratory, where we study the biology of myeloma cells and develop potential new drugs and immunotherapies. It also includes clinical research in which our scientists test new methods for treating and caring for myeloma patients. It spans years and decades as we track survivors’ quality of life after treatment.



Fred Hutch researchers are contributing landmark discoveries about how to engineer immune cells called T cells to target the multiple myeloma. Our scientists are also developing new myeloma drugs based on antibodies, which are disease-targeting immune proteins. We are also leaders in radioimmunotherapy, in which antibodies ferry powerful radioactive isotopes straight to myeloma cells.

Blood Stem Cell (Hematopoietic) Transplantation


Fred Hutch scientists are improving blood stem-cell transplantation to save the lives of more people with multiple myeloma. 

We are learning the secrets of immune genetics to find better-matched donors for each patient and developing less toxic transplantation regimens. Our researchers are also developing newer forms of transplantation that can offer a patient a good chance of success even without a fully matched donor. 

All of these advances are informed by our research on the fundamental biology of blood-forming cells, the immune system and myeloma itself.

Survivorship and Treatment Complications


During and after treatment for multiple myeloma, patients can experience numerous side effects that can affect their physical, emotional and social functioning. Fred Hutch scientists are developing supportive care for myeloma patients to protect them from treatment complications and improve their quality of life. They are also studying the long-term and late effects of treatment.

In particular, our scientists are world experts on the complications of blood stem-cell transplantation, including infections and graft-vs.-host disease. Our scientists are learning how these complications occur and developing better methods to prevent and treat them.

Immunotherapy Integrated Research Center (IIRC)

Our researchers are developing new ways to empower a patient’s own immune system to do what it does naturally — fight disease — with potentially fewer side effects than conventional cancer treatments. The IIRC is dedicated to creating partnerships across Fred Hutch to develop the next generation of these immunotherapies for cancers and other deadly diseases. 

Selected Multiple Myeloma Clinical Trials

Clinical research is an essential part of the scientific process that leads to new treatments and better care. Clinical trials can also be a way for patients to get early access to new cutting-edge therapies. Our clinical research teams are running clinical studies on various kinds of multiple myeloma.

See All Multiple Myeloma Clinical Trials

Fred Hutchinson Cancer Research Center campus.

Our Multiple Myeloma Researchers

Our interdisciplinary scientists and clinicians work together to prevent, diagnose and treat multiple myeloma as well as other cancers and diseases.

Seattle Cancer Care Alliance building.

Patient Treatment & Care

Seattle Cancer Care Alliance, our clinical care partner, gives patients access to the comprehensive, world-class treatments developed at Fred Hutch.


A Patient’s Story

Todd Hirai

Todd Hirai 

Todd Hirai, a Seattle father of three, thought he'd wrenched his back at baseball practice. But after physical therapy failed to ease his back pain, he learned that he had high-risk multiple myeloma, a diagnosis that is associated with an average survival time of just three years. His only real shot at survival was a three-part treatment sequence that was part of a clinical trial at Fred Hutch, involving two types of bone marrow transplant followed by a cancer-suppressing drug.

Latest Multiple Myeloma News

Dr. Brenda Sandmaier named president of American Society for Transplantation and Cellular Therapy Transplant immunotherapy physician-scientist will serve 2022-2023 term April 26, 2022
What's next for T-cell therapies: Q&A with Dr. Stanley Riddell After approval of latest cellular therapy for non-Hodgkin lymphoma, the immunologist looks ahead February 5, 2021
Scientists predict progress against COVID-19, cancer in 2021 After a challenging and deadly 2020, some hopeful predictions for the new year December 22, 2020
Last Modified, December 01, 2021